Navigation Links
MammaPrint(R) Breast Cancer Test Provides Valuable Insight for Personalized Treatment Decisions
Date:5/30/2008

Results presented at major U.S. cancer conference

CHICAGO, May 30 /PRNewswire/ -- Agendia BV, a world leader in the rapidly evolving field of molecular diagnostics, announced today that data from two studies involving its MammaPrint(R) breast cancer prognosis test will be presented at the American Society of Clinical Oncology's (ASCO) annual meeting. Collectively, these findings show that MammaPrint, a prognostic test for breast cancer recurrence using a 70-gene signature, provides important information for more effective patient management.

"These studies demonstrate the clinical utility of MammaPrint in helping physicians make more informed decisions about the course of care for their patients with breast cancer," said Laura van 't Veer, Ph.D., Head of Molecular Pathology at the Netherlands Cancer Institute in Amsterdam, who participated in both studies. "Prognostic tests such as MammaPrint have ushered in a new era in personalized medicine, helping us to determine the most appropriate care based on an individual patient's risk and treatment preferences. This might mean, in some cases, avoiding harsh therapies that may otherwise not be effective."

In the first study (abstract #527), conducted at The University of Texas M.D. Anderson Cancer Center in Houston, tumor samples from 198 patients with early stage, lymph-node negative breast cancer were analyzed with multiple gene-expression assays, including MammaPrint, to determine whether both prognostic and treatment prediction data could be generated from a single specimen.

Among 32% of patients (64 of 198) predicted to be at low risk for breast cancer recurrence with MammaPrint, 31% (20 of 64) were predicted to be highly sensitive to endocrine therapy while 88% (56 of 64) were predicted to be insensitive to chemotherapy. The remaining 134 patients who were considered to be at high risk for cancer recurrence, were predominantly predicted chemo-sensitive (>51%). The abstract
'/>"/>

SOURCE Agendia BV
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4

Related biology technology :

1. MammaPrint(R) Breast Cancer Test Validated in Lymph Node-Positive Breast Cancer Patients
2. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
3. GlaxoSmithKline Recognizes University of Michigans Dr. Daniel F. Hayes as the First Recipient of the Gianni Bonadonna Breast Cancer Award
4. Imaging Diagnostic Systems New Laser Breast Imaging Scanner Introduced in Malaysia
5. NeoMatrix Announces Additional Funding for Breakthrough Breast Cancer Screening Test
6. Largest Asian Cancer Hospital to Evaluate New CT Laser Breast Imaging System
7. Cellumen Establishes Collaboration in Breast Cancer Patient Stratification
8. Celebrities and Notables From the Worlds of Film, Television, Music and Sports Join Lifetime Televisions 13th Annual Multi-Platform Stop Breast Cancer For Life Campaign
9. Agendia Acquires Rights to the Discovery of a Major Drug Resistance Mechanism in Breast Cancer Potentially Leading to a Herceptin(R) Sensitivity Test
10. FDA Approves IXEMPRA(TM) (ixabepilone), a Semi-Synthetic Analog of Epothilone B, for the Treatment of Advanced Breast Cancer
11. Panacea Pharmaceuticals Announces the Availability of BC Detect(SM), a Serum- Based Diagnostic Test for Breast Cancer

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/2/2009)... , SHANGHAI, Dec. 2 /PRNewswire-Asia/ ... markets are in turmoil and uncertainty is part of... the pharma industry has been,relatively immune to...ke a,vacation. , During the midst of the ...t Johnson & Johnson inaugurated an R&D cen...
(Date:12/1/2009)... , INCLINE VILLAGE, Nev., Dec. 1 /PRNewswire-F...DLI ) today announced revenue guidance for the fou...ly $57 million, as compared with $69 million for t...ter 2008 results was the first of two installment ...uded in fourth quarter 2008 results was a one-time...
(Date:12/1/2009)... , PLYMOUTH, Mass., Dec. 1 Ha...nnounced today results from the company sponsored ...ndra Medical Center in Chennai, India using the co...onstructable Critical Limb Ischemia (CLI). Sri Ram...national-associated institution based in Chennai, ...
(Date:12/1/2009)... , SARASOTA, Fla., Dec. 1 E..., Osprey Biotechnics Inc. of Sarasota has appointe...ributor. ,, Lake is located near Birmingham, E...al bacteria which serve the agricultural, waste wa...red to be hungry and to open drain fields, and cle...
Breaking Biology Technology:Pharma and Biotech Leaders to Converge in China at Asia Pharma R&D Leaders 2010 Summit 2Pharma and Biotech Leaders to Converge in China at Asia Pharma R&D Leaders 2010 Summit 3PDL BioPharma Provides Fourth Quarter 2009 Revenue Guidance of Approximately $57 Million 2PDL BioPharma Provides Fourth Quarter 2009 Revenue Guidance of Approximately $57 Million 3Harvest Technologies Announces Trial Results in its India Study Using BMAC to Treat Patients With Non-Reconstructable Critical Limb Ischemia 2Harvest Technologies Announces Trial Results in its India Study Using BMAC to Treat Patients With Non-Reconstructable Critical Limb Ischemia 3
...cer Center physicians today released results of re...o Agent Orange have greatly increased risks of pro... most aggressive form of the disease as compared t...ch appear online now and will be published in the ...e first to reliably link the herbicide with this f...
... years in secret. , Most people did not know that...ion department at Sandia National Laboratories was...nvestigation of letters containing bacillus anthra...e spores were mailed in the fall of 2001 to severa...e people were killed. , Sandia,s work demonstrate...
...A new interactive web lesson teaches upper-level u...rbicides are developed. The lesson, developed by W...seal of approval by the Journal of Natural Resour...in the 2008 issue. , Surprisingly, almost all of ... by random searching. Collections of chemicals fro...
Other Biology Technology:Exposure to Agent Orange linked to prostate cancer in Vietnam veterans 2FBI unveils science of anthrax investigation 2FBI unveils science of anthrax investigation 3
(Date:12/2/2009)...gia College of Veterinary Medicine have made an "u...ues for treating Ichthyophthirius multifiliis, or ...ite that commonly attacks freshwater fish. , Wit...found that Ich harbors two apparently symbiotic in...lly found free-living, and Rickettsia, which are o...
(Date:12/2/2009)...pleased to announce the 2009 winner of the Interna...r Distinguished Service Professor Emeritus, Depart...iology, The University of Chicago, USA. , The P...th anniversary of the Manpei Suzuki Diabetes Found...hers in the field of diabetes around the world wit...
(Date:12/2/2009)...before the thought telling it to flex can race dow...on channelmust open in the surface of each cell in...spur the cell to action. New research* at the Nati...has allowed scientists to observe ion channels wit...tially offering insights for future drug developme...
Breaking Biology News(10 mins):UGA researchers lead team in discovery involving devastating freshwater fish parasite, 'Ich' 2UGA researchers lead team in discovery involving devastating freshwater fish parasite, 'Ich' 3Nervy research: Researchers take initial look at ion channels in a model system 2Award Winning Actress and Director Anjelica Huston Selected as Honorary Chair for L A Jewish Homes Walk of Ages X 55533 1Award Winning Actress and Director Anjelica Huston Selected as Honorary Chair for L A Jewish Homes Walk of Ages X 55533 2Award Winning Actress and Director Anjelica Huston Selected as Honorary Chair for L A Jewish Homes Walk of Ages X 55533 3Caraco Pharmaceutical Laboratories Ltd Announces Reversal of Summary Judgment in Ultracet 28R 29 ANDA Patent Litigation 55531 1Caraco Pharmaceutical Laboratories Ltd Announces Reversal of Summary Judgment in Ultracet 28R 29 ANDA Patent Litigation 55531 2CenterWatch Celebrates 15 Year Milestone as Leading Information Provider for the Clinical Trials Industry 55529 1CenterWatch Celebrates 15 Year Milestone as Leading Information Provider for the Clinical Trials Industry 55529 2
...sing techniques that could revolutionize manufactu... carbon nanotubes that are the longest in the worl...ng, each nanotube is 900,000 times longer than its...to be longer, stronger and better conductors of el...uld ultimately find use in smart fabrics, sensors ...
... new vaccine aimed at preventing cervical cancer i...es of the human papillomavirus (HPV) responsible f...ionwide study of the vaccine will be published in ...cine. , Cervical cancer is the second most common ...ng in nearly half a million diagnoses and 240,000 ...
...he causes of "broken heart syndrome" remain a myst...ognizing and treating this rare, life-threatening ...th Annual Scientific Sessions of the Society for C..., May 9?2, 2007, in Orlando, FL. , Researchers fro...ed the largest registry of patients in the United ...
Other Biology News:The longest carbon nanotubes you've ever seen 2Study shows continued success for new HPV vaccine against virus responsible for cervical cancer 2Study offers clues to 'Broken Heart Syndrome' 2Study offers clues to 'Broken Heart Syndrome' 3
...yclonal antibody to human XAB2 (amino terminus) X...hrough its interaction with XPA. Immunoprecipitati...ion of XAB2 interacts with the transcription-coupl... with RNA polymerase II. Microinjection experiment...
Bio-Plex MCV Plate III from Bio-Rad
...RP Conjugation Kits are based on well-established ...hat are consistent and reproducible. This kit cont...in or antibody, including ready-to-use buffers and...pplied ready-to-use and requires no activation or ...
Acridinium NHS ester from Cayman Chemical
Biology Products: